Clinical Trial Update: Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) [Phase 3]

View source ↗

Summary

Nuvation Bio is conducting a Phase 3 trial (TRUST-IV) of taletrectinib vs placebo as adjuvant therapy in ROS1-positive non-small cell lung cancer; recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taletrectinib (taletrectinib)

Snippet

Sponsor: Nuvation Bio Inc. | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING